studies

mHNSCC - L2 - PDL1 positive, immune chekpoint inhibitors vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsKEYNOTE-040 (CPS >1), 2018 0.74 [0.58; 0.94] 0.74[0.58; 0.94]KEYNOTE-040 (CPS >1), 201810%387NAnot evaluable progression or deaths (PFS)detailed resultsKEYNOTE-040 (CPS >1), 2018 1.01 [0.81; 1.26] 1.01[0.81; 1.26]KEYNOTE-040 (CPS >1), 201810%387NAnot evaluable objective responses (ORR)detailed resultsKEYNOTE-040 (CPS >1), 2018 1.90 [1.04; 3.47] 1.90[1.04; 3.47]KEYNOTE-040 (CPS >1), 201810%387NAnot evaluable0.55.01.0relative treatment effectwww.metaEvidence.org2024-09-21 00:54 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 114 - treatments: 204,504,850,329,558,579,549,868,502,741,556,812,813,367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,1561,854,374,953,672,1080,1560,1073,862,1562,1565,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258,1563,746,745,856,634,861,416,864,769,980,369,743

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons